Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Which Offers More Control: Index Fund Or Target Date Retirement. Understand where you have more say over allocations and timing for retirement planning.
28,368 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
PulteGroup accelerates its shift toward build-to-order homes to support margins as the 2026 housing market stays vola...
The VanEck PFXF ETF focuses on non-financial preferred securities, offering a ~6.7% yield. But investors must watch c...
A cost gap between IVW and cheaper growth peers may quietly erode returns over time. This analysis breaks down fees, ...
When a well-known TV host shares an aggressive cancer diagnosis, it highlights the financial realities many face afte...
If president donald trump just signals a major crypto push, investors face a fast-moving regulatory landscape. This g...
When vertex stock rising today captures headlines, investors should look beyond the flash. This guide explains the wh...
As July 2026 brings steady rates, households weigh HYSA against Treasury Bills for emergency funds. The decision hing...
Two popular dividend ETFs battle for income investors: ProShares NOBL and iShares HDV. This guide breaks down strateg...
SpaceX activists and market watchers are neck-deep in debate over a potential IPO that could fetch a multi-trillion-d...
Bitcoin trades below $65k, yet Polymarket participants are betting on a $150k price by year-end 2026. This article ex...
A simple, durable approach to building income: three passive income ETFs worth holding for the long haul. Learn how t...